News about "Biocon"

Viatris to Receive USD 400 Million in Cash and USD 415 Million in Equity Shares of Biocon

Viatris is set to receive USD 400 million in cash and USD 415 million in Biocon equity shares as part of a revised agreement, accelerating the end of non-compete restrictions in the biosimilars space and enabling both companies to pursue expanded market opportunities.

Biocon | 08/12/2025 | By Dineshwori

Biocon Clarifies Media Reports on Possible Biocon Biologics Merger

Biocon has issued a clarification regarding recent media reports suggesting that the company is considering a potential merger of its unlisted subsidiary, Biocon Biologics Ltd. (BBL), along with IPO and share swap options.

Biocon | 14/11/2025 | By Dineshwori |  176

Biocon Posts Robust Q2FY26 Results as Biosimilars and Generics Drive Double-Digit Growth

Biocon reported a robust financial performance for the second quarter of FY26, with total revenue rising 21 percent year-on-year (YoY) to INR 4,389 crore, compared to INR 3,623 crore in Q2 FY25.

Biocon | 12/11/2025 | By Dineshwori |  220

Biocon's Cranbury Facility in US Passes FDA Inspection, Supports Expansion Plans

Biocon’s inspection concluded with a single observation, which the company will address within the stipulated timeframe, and it is not expected to impact ongoing business operations

Biocon | 15/10/2025 | By Dineshwori |  148

Enzene, Aurobindo and Biocon Boost US Manufacturing with Major New Jersey Expansions

This month, three leading Indian firms — Enzene Biosciences, Aurobindo Pharma, and Biocon — have inaugurated major facilities in New Jersey, underscoring a growing trend of onshore investment by Indian pharma companies.

Biocon | 18/09/2025 | By Dineshwori |  301

Biocon Opens First US Manufacturing Facility in New Jersey

The Cranbury facility will help Biocon diversify its manufacturing base, strengthen its supply chain
and accelerate the expansion of its global footprint.

Biocon | 11/09/2025 | By Dineshwori |  121

Biocon Biologics Secures FDA Approval for Kirsty

Biocon Biologics has announced that it has received FDA approval for KIRSTY (Insulin Aspart-xjhz), making it the first and only interchangeable biosimilar to NovoLog in the US, marking a major milestone in expanding affordable insulin options.

Biocon | 16/07/2025 | By Mrinmoy Dey |  237

Biocon Biologics Receives European Commission Nod for Denosumab Biosimilars to Improve Bone Health

Biocon Biologics has received European Commission approval for its Denosumab biosimilars, Vevzuo and Evfraxy, thereby expanding access to advanced treatments for bone-related conditions across the EU.

Biocon | 03/07/2025 | By Mrinmoy Dey |  172

Biocon Join Hands with Tabuk Pharma to Commercialize its GLP -1 Products in Middle East

The agreement also provides for a provision to expand to other GLP products, as well as the option of a tech transfer that will enable localized manufacturing at a later stage.

Biocon | 27/09/2024 | By Aishwarya |  759

Biocon Signs Exclusive Deal for Commercializing Liraglutide in South Korea with Handok

Biocon Ltd. has signed an exclusive licensing and supply agreement with Handok, a specialty pharmaceutical company in South Korea, for the commercialization of its vertically integrated, complex drug product, Synthetic Liraglutide.

Biocon | 28/05/2024 | By Aishwarya |  684